CFTR Modulator Combination Therapy for Defective Protein Trafficking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly those using CFTR correctors, are not sufficiently effective, and there is a need for novel therapies to address the ion and fluid transport imbalances caused by CFTR mutations, which lead to respiratory and gastrointestinal issues, infertility, and increased microbial infections.
Innovation Solution
Development of a CFTR-modulating compound, (6R,12R)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadeca-1(18),2,4,16-pentaen-6-ol, and its deuterated derivatives, along with pharmaceutically acceptable salts, which can be administered alone or in combination with other CFTR-modulating agents to enhance CFTR activity and correct defective protein processing and trafficking.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If CFTR correctors are used as monotherapy, then the treatment approach is simple, but the effectiveness is insufficient
Solution Approach 1:
The patent combines a CFTR corrector and a CFTR potentiator into a single combination therapy regimen. The corrector component improves faulty protein processing and trafficking to the epithelial surface, while the potentiator component increases channel gating activity of mutant and wild-type CFTR at the epithelial cell surface. This merging of two mechanisms of action resolves the contradiction by maintaining treatment simplicity through a single approved combination while achieving superior effectiveness compared to monotherapy.
2Reliability
If combination therapy with corrector and potentiator is used, then CFTR activity is enhanced, but treatment complexity increases
Solution Approach 1:
The patent utilizes already-approved CFTR modulator drugs in combination, where the corrector and potentiator are both individually approved by regulatory authorities. This approach enhances CFTR activity through dual mechanism action while minimizing treatment complexity by using established, well-characterized therapies with known safety profiles and administration protocols, rather than requiring entirely new combination regimens.
3Reliability
If novel CFTR modulators are developed, then treatment effectiveness is improved, but development time and cost increase
Solution Approach 1:
The patent leverages CFTR modulators that have already undergone extensive preclinical and clinical development, including approval by regulatory authorities. By utilizing these preliminarily developed and validated compounds in combination therapy, the approach achieves enhanced treatment effectiveness without incurring the full time and cost burden of de novo drug development, as the individual components have already been optimized and approved for use.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This disclosure provides methods of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure also provides pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, and optionally comprising one or more additional CFTR-modulating agents.